Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme

The approvals of nintedanib and pirfenidone changed the treatment paradigm in idiopathic pulmonary fibrosis (IPF), and increased our understanding of the underlying disease mechanisms. Nonetheless, many challenges and unmet needs remain in the management of patients with IPF and other progressive fi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Valenzuela, Claudia (VerfasserIn) , Torrisi, Sebastiano Emanuele (VerfasserIn) , Kahn, Nicolas (VerfasserIn) , Quaresma, Manuel (VerfasserIn) , Stowasser, Susanne (VerfasserIn) , Kreuter, Michael (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: [2020]
In: Respiratory research
Year: 2020, Jahrgang: 21
ISSN:1465-993X
DOI:10.1186/s12931-019-1269-6
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/s12931-019-1269-6
Volltext
Verfasserangaben:Claudia Valenzuela, Sebastiano Emanuele Torrisi, Nicolas Kahn, Manuel Quaresma, Susanne Stowasser, Michael Kreuter

MARC

LEADER 00000caa a2200000 c 4500
001 1693475723
003 DE-627
005 20230427033652.0
007 cr uuu---uuuuu
008 200330s2020 xx |||||o 00| ||eng c
024 7 |a 10.1186/s12931-019-1269-6  |2 doi 
035 |a (DE-627)1693475723 
035 |a (DE-599)KXP1693475723 
035 |a (OCoLC)1341311424 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Valenzuela, Claudia  |e VerfasserIn  |0 (DE-588)1207283738  |0 (DE-627)1693476932  |4 aut 
245 1 0 |a Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme  |c Claudia Valenzuela, Sebastiano Emanuele Torrisi, Nicolas Kahn, Manuel Quaresma, Susanne Stowasser, Michael Kreuter 
264 1 |c [2020] 
300 |b Illustrationen 
300 |a 151 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 30.03.2020 
520 |a The approvals of nintedanib and pirfenidone changed the treatment paradigm in idiopathic pulmonary fibrosis (IPF), and increased our understanding of the underlying disease mechanisms. Nonetheless, many challenges and unmet needs remain in the management of patients with IPF and other progressive fibrosing interstitial lung diseases. 
700 1 |a Torrisi, Sebastiano Emanuele  |e VerfasserIn  |0 (DE-588)1190667231  |0 (DE-627)1669225615  |4 aut 
700 1 |a Kahn, Nicolas  |d 1982-  |e VerfasserIn  |0 (DE-588)1023650371  |0 (DE-627)718423941  |0 (DE-576)367217635  |4 aut 
700 1 |a Quaresma, Manuel  |e VerfasserIn  |4 aut 
700 1 |a Stowasser, Susanne  |e VerfasserIn  |4 aut 
700 1 |a Kreuter, Michael  |d 1972-  |e VerfasserIn  |0 (DE-588)122645995  |0 (DE-627)082066795  |0 (DE-576)293362742  |4 aut 
773 0 8 |i Enthalten in  |t Respiratory research  |d London : BioMed Central, 2001  |g 21(2020) Artikel-Nummer 7, 15 Seiten  |h Online-Ressource  |w (DE-627)326646485  |w (DE-600)2041675-1  |w (DE-576)107014823  |x 1465-993X  |7 nnas  |a Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme 
773 1 8 |g volume:21  |g year:2020  |g extent:151  |a Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme 
856 4 0 |u https://doi.org/10.1186/s12931-019-1269-6  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20200330 
993 |a Article 
994 |a 2020 
998 |g 122645995  |a Kreuter, Michael  |m 122645995:Kreuter, Michael  |d 910000  |d 950000  |d 950900  |d 50000  |e 910000PK122645995  |e 950000PK122645995  |e 950900PK122645995  |e 50000PK122645995  |k 0/910000/  |k 1/910000/950000/  |k 2/910000/950000/950900/  |k 0/50000/  |p 6  |y j 
998 |g 1023650371  |a Kahn, Nicolas  |m 1023650371:Kahn, Nicolas  |d 910000  |d 950000  |d 950900  |e 910000PK1023650371  |e 950000PK1023650371  |e 950900PK1023650371  |k 0/910000/  |k 1/910000/950000/  |k 2/910000/950000/950900/  |p 3 
999 |a KXP-PPN1693475723  |e 3615654684 
BIB |a Y 
SER |a journal 
JSO |a {"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1693475723","note":["Gesehen am 30.03.2020"],"language":["eng"],"person":[{"given":"Claudia","roleDisplay":"VerfasserIn","role":"aut","display":"Valenzuela, Claudia","family":"Valenzuela"},{"family":"Torrisi","display":"Torrisi, Sebastiano Emanuele","role":"aut","roleDisplay":"VerfasserIn","given":"Sebastiano Emanuele"},{"display":"Kahn, Nicolas","given":"Nicolas","role":"aut","roleDisplay":"VerfasserIn","family":"Kahn"},{"given":"Manuel","roleDisplay":"VerfasserIn","role":"aut","display":"Quaresma, Manuel","family":"Quaresma"},{"roleDisplay":"VerfasserIn","role":"aut","given":"Susanne","display":"Stowasser, Susanne","family":"Stowasser"},{"given":"Michael","role":"aut","roleDisplay":"VerfasserIn","display":"Kreuter, Michael","family":"Kreuter"}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisher":"BioMed Central","dateIssuedDisp":"2001-","publisherPlace":"London","dateIssuedKey":"2001"}],"disp":"Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programmeRespiratory research","language":["eng"],"title":[{"title_sort":"Respiratory research","title":"Respiratory research"}],"id":{"issn":["1465-993X"],"zdb":["2041675-1"],"eki":["326646485"]},"pubHistory":["1.2000 -"],"type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 04.08.22"],"recId":"326646485","part":{"text":"21(2020) Artikel-Nummer 7, 15 Seiten","year":"2020","extent":"151","volume":"21"}}],"name":{"displayForm":["Claudia Valenzuela, Sebastiano Emanuele Torrisi, Nicolas Kahn, Manuel Quaresma, Susanne Stowasser, Michael Kreuter"]},"id":{"eki":["1693475723"],"doi":["10.1186/s12931-019-1269-6"]},"physDesc":[{"noteIll":"Illustrationen","extent":"151 S."}],"origin":[{"dateIssuedKey":"2020","dateIssuedDisp":"[2020]"}],"title":[{"title_sort":"Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme","title":"Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme"}]} 
SRT |a VALENZUELAONGOINGCHA2020